What question did this study set out to answer?

This study aims to define the intrinsic features of CAR-T products that predict durable responses in multiple myeloma patients.

June 13, 2026Blood

Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates NF-κB features in CAR-T products, indicating potential for improved responses in multiple myeloma.

This study aims to define the intrinsic features of CAR-T products that predict durable responses in multiple myeloma patients.
Profiles 40 idecabtagene vicleucel infusion products using single-cell RNA sequencing.
Analyses include evaluation of CD4 CAR-T cell transcriptional programs and intrinsic markers of T-cell fitness.
Investigates the impact of pharmacologic inhibition of NF-κB on CAR-T efficacy in vitro.
Identified NF-κB-driven transcriptional programs correlated with prolonged progression-free and overall survival.
Demonstrated that elevated NF-κB activity serves as an intrinsic marker of T-cell fitness.
Pharmacologic inhibition of NF-κB significantly reduced CAR-T cytotoxicity and cytokine production in vitro.

Noble et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark